ICVX ICOSAVAX INC

Icosavax to Participate in the Jefferies London Healthcare Conference

Icosavax to Participate in the Jefferies London Healthcare Conference

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023 in London, UK.

Jefferies London Healthcare Conference

  • Adam Simpson, Chief Executive Officer of Icosavax, will participate in a fireside chat in London on Wednesday, November 15 at 4:00 pm GMT (11:00 am ET).

Interested parties can register for and access the live webcast for this conference by visiting the “” section of the Icosavax website. The webcast replay will be available after the conclusion of the presentation.

About Icosavax

Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.

For more information, visit .

Media Contact:

Jessica Yingling, Ph.D.,

Little Dog Communications Inc.



858.344.8091

Investor Contact:

Laurence Watts

Gilmartin Group, LLC



619.916.7620



EN
08/11/2023

Underlying

ICVXICOSAVAX INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ICOSAVAX INC

 PRESS RELEASE
Free
ICVX ICOSAVAX INC

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca - Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right (CVR) of up to $5.00 per share - - Representing a total equity value of up to $1.1 billion including the CVR - SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX) today announced it has entered into a definitive agreement pursuant to which AstraZeneca, through an acquisition subsidiary, will initiate a tender offer to acquire all of Icosavax’s outstanding shares for a price of $15.00 per sha...

December 12, 2023 1 EN
 PRESS RELEASE
Free
ICVX ICOSAVAX INC

Icosavax Announces Positive Topline Interim Phase 2 Results for Combin...

Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults – IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data – SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision...

December 12, 2023 1 EN
 PRESS RELEASE
Free
ICVX ICOSAVAX INC

Icosavax Reports Third Quarter 2023 Financial Results and Provides Cor...

Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023 - - Completed candidate selection for SARS-CoV-2 and influenza programs, highlighting company’s antigen design capabilities - - Cash and cash equivalents, and short-term investments of $229.2 million at end 3Q 2023 - SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharma...

November 14, 2023 1 EN
 PRESS RELEASE
Free
ICVX ICOSAVAX INC

Icosavax to Participate in the Jefferies London Healthcare Conference

Icosavax to Participate in the Jefferies London Healthcare Conference SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023 in ...

November 8, 2023 1 EN
 PRESS RELEASE
Free
ICVX ICOSAVAX INC

Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual ...

Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Guggenheim Healthcare Talks ...

October 31, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch